Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -559.78M | -644.76M | -715.54M | -649.13M | -574.78M |
| Total Depreciation and Amortization | 84.04M | 83.70M | 77.17M | 63.33M | 48.45M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.05M | 175.56M | 196.91M | 176.45M | 153.66M |
| Change in Net Operating Assets | 11.74M | 13.69M | 296.00K | 26.33M | -16.16M |
| Cash from Operations | -320.95M | -371.81M | -441.17M | -383.03M | -388.83M |
| Capital Expenditure | -4.90M | -6.47M | -6.52M | -10.84M | -8.87M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 277.10M | 277.10M | 277.10M |
| Divestitures | 0.00 | -4.44M | -4.44M | -4.44M | -4.44M |
| Other Investing Activities | -5.04M | -5.96M | -6.31M | -4.01M | -4.35M |
| Cash from Investing | -9.94M | -16.87M | 259.83M | 257.82M | 259.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.59M | -8.43M | -8.36M | -8.52M | -6.46M |
| Issuance of Common Stock | 490.38M | 531.41M | 409.97M | 175.26M | 335.66M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4.26M | -1.45M | -1.45M | -1.45M | 1.55M |
| Cash from Financing | 477.54M | 521.53M | 400.17M | 165.29M | 330.75M |
| Foreign Exchange rate Adjustments | 9.38M | 18.04M | 12.49M | 11.02M | 1.65M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 156.02M | 150.90M | 231.31M | 51.09M | 203.01M |